0 5 Human human JJ 6 14 monocyte monocyte NN 15 22 binding bind VBG 23 25 to to TO 26 37 fibronectin fibronectin NN 38 46 enhances enhance VBZ 47 64 IFN-gamma-induced ifn-gamma-induced JJ 65 70 early early JJ 71 80 signaling signaling NN 81 87 events event NNS 87 88 . . . 90 99 Leukocyte Leukocyte NNP 100 109 integrins integrin NNS 110 113 are be VBP 114 127 fundamentally fundamentally RB 128 137 important important JJ 138 140 in in IN 141 151 modulating modulate VBG 152 160 adhesion adhesion NN 161 163 to to TO 164 177 extracellular extracellular JJ 178 184 matrix matrix NN 185 195 components component NNS 196 199 and and CC 200 202 to to TO 203 208 other other JJ 209 214 cells cell NNS 214 215 . . . 216 220 This this DT 221 238 integrin-mediated integrin-mediated JJ 239 247 adhesion adhesion NN 248 256 controls control VBZ 257 266 leukocyte leukocyte NN 267 273 arrest arrest NN 274 277 and and CC 278 291 extravasation extravasation NN 292 298 during during IN 299 302 the the DT 303 308 onset onset NN 309 311 of of IN 312 324 inflammatory inflammatory JJ 325 334 responses response NNS 334 335 . . . 336 344 Moreover moreover RB 344 345 , , , 346 361 integrin-ligand integrin-ligand JJ 362 374 interactions interaction NNS 375 382 trigger trigger VBP 383 392 signaling signaling NN 393 401 pathways pathway NNS 402 406 that that WDT 407 410 may may MD 411 420 influence influence VB 421 430 leukocyte leukocyte NN 431 440 phenotype phenotype NN 441 444 and and CC 445 453 function function NN 454 456 at at IN 457 462 sites site NNS 463 465 of of IN 466 478 inflammation inflammation NN 478 479 . . . 480 482 In in IN 483 486 the the DT 487 494 current current JJ 495 502 studies study NNS 502 503 , , , 504 506 we we PRP 507 516 evaluated evaluate VBD 517 520 the the DT 521 534 combinatorial combinatorial JJ 535 542 effects effect NNS 543 545 of of IN 546 554 monocyte monocyte NN 555 563 adhesion adhesion NN 564 567 and and CC 568 577 IFN-gamma IFN-gamma NNP 578 580 on on IN 581 594 intracellular intracellular JJ 595 604 signaling signaling NN 605 613 pathways pathway NNS 613 614 . . . 615 624 IFN-gamma IFN-gamma NNP 625 633 triggers trigger VBZ 634 635 a a DT 636 648 well-defined well-defined JJ 649 655 signal signal NN 656 668 transduction transduction NN 669 676 pathway pathway NN 676 677 , , , 678 683 which which WDT 684 692 although although IN 693 696 not not RB 697 705 directly directly RB 706 716 stimulated stimulate VBN 717 719 by by IN 720 728 monocyte monocyte NN 729 738 adherence adherence NN 739 741 to to TO 742 753 fibronectin fibronectin NN 754 756 or or CC 757 783 arginine-glycine-aspartate arginine-glycine-aspartate NN 784 785 ( ( ( 785 796 RGD)-coated rgd)-coated JJ 797 806 substrata substrata NNS 806 807 , , , 808 811 was be VBD 812 820 enhanced enhance VBN 821 834 significantly significantly RB 835 837 in in IN 838 843 these these DT 844 859 matrix-adherent matrix-adherent JJ 860 865 cells cell NNS 865 866 . . . 867 875 Compared compare VBN 876 880 with with IN 881 890 monocytes monocyte NNS 891 893 in in IN 894 904 suspension suspension NN 905 907 or or CC 908 916 adherent adherent JJ 917 919 on on IN 920 927 plastic plastic JJ 928 936 surfaces surface NNS 936 937 , , , 938 947 monocytes monocyte NNS 948 956 adherent adherent JJ 957 959 to to TO 960 971 fibronectin fibronectin NN 972 974 or or CC 975 978 RGD rgd NN 979 988 exhibited exhibit VBD 989 990 a a DT 991 998 greater great JJR 999 1003 than than IN 1004 1013 threefold threefold JJ 1014 1022 increase increase NN 1023 1025 in in IN 1026 1032 steady steady JJ 1033 1038 state state NN 1039 1045 levels level NNS 1046 1048 of of IN 1049 1066 IFN-gamma-induced ifn-gamma-induced JJ 1067 1071 mRNA mRNA NNP 1072 1075 for for IN 1076 1079 the the DT 1080 1084 high high JJ 1085 1093 affinity affinity NN 1094 1096 Fc Fc NNP 1097 1104 gammaRI gammaRI NNP 1105 1113 receptor receptor NN 1113 1114 . . . 1115 1117 By by IN 1118 1133 electrophoretic electrophoretic JJ 1134 1142 mobility mobility NN 1143 1148 shift shift NN 1149 1155 assays assay NNS 1155 1156 , , , 1157 1161 this this DT 1162 1170 increase increase NN 1171 1173 in in IN 1174 1178 mRNA mRNA NNP 1179 1182 was be VBD 1183 1193 associated associate VBN 1194 1198 with with IN 1199 1200 a a DT 1201 1203 5- 5- CD 1204 1206 to to TO 1207 1214 10-fold 10-fold JJ 1215 1223 increase increase NN 1224 1226 in in IN 1227 1230 the the DT 1231 1247 STAT1-containing stat1-containing JJ 1248 1259 DNA-binding dna-binding JJ 1260 1267 complex complex NN 1268 1272 that that WDT 1273 1278 binds bind VBZ 1279 1281 to to TO 1282 1284 Fc Fc NNP 1285 1292 gammaRI gammaRI NNP 1293 1301 promoter promoter NN 1302 1310 elements element NNS 1310 1311 . . . 1312 1323 Furthermore furthermore RB 1323 1324 , , , 1325 1328 the the DT 1329 1337 tyrosine tyrosine NN 1338 1353 phosphorylation phosphorylation NN 1354 1356 of of IN 1357 1362 STAT1 STAT1 NNP 1363 1366 and and CC 1367 1370 the the DT 1371 1379 tyrosine tyrosine NN 1380 1387 kinases kinase NNS 1388 1392 JAK1 jak1 NN 1393 1396 and and CC 1397 1401 JAK2 JAK2 NNP 1402 1405 was be VBD 1406 1414 enhanced enhance VBN 1415 1428 significantly significantly RB 1429 1431 in in IN 1432 1444 RGD-adherent rgd-adherent JJ 1445 1454 monocytes monocyte NNS 1455 1463 compared compare VBN 1464 1468 with with IN 1469 1476 control control NN 1477 1482 cells cell NNS 1482 1483 . . . 1484 1489 These these DT 1490 1497 results result NNS 1498 1505 suggest suggest VBP 1506 1507 a a DT 1508 1513 novel novel JJ 1514 1523 mechanism mechanism NN 1524 1526 by by IN 1527 1532 which which WDT 1533 1550 integrin-mediated integrin-mediated JJ 1551 1555 cell cell NN 1556 1564 adhesion adhesion NN 1565 1568 can can MD 1569 1577 modulate modulate VB 1578 1581 the the DT 1582 1591 magnitude magnitude NN 1592 1594 of of IN 1595 1611 cytokine-induced cytokine-induced JJ 1612 1618 signal signal NN 1619 1631 transduction transduction NN 1632 1640 pathways pathway NNS 1640 1641 , , , 1642 1649 thereby thereby RB 1650 1660 amplifying amplify VBG 1661 1669 cellular cellular JJ 1670 1676 events event NNS 1677 1684 leading lead VBG 1685 1687 to to TO 1688 1696 monocyte monocyte NN 1697 1707 activation activation NN 1708 1711 and and CC 1712 1724 inflammation inflammation NN 1724 1725 . . .